Researchers Identified CD70 as Lymphoma Immune Target
A study explored a potential new approach to help the immune system recognize and fight resistant mantle cell lymphoma.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust that early-stage laboratory medical research will result in successful patient treatments?
Researchers at MD Anderson Cancer Center discovered that CD70 expression allows mantle cell lymphoma cells to evade the immune system. This finding, published in 2026, could provide a foundation for developing new therapies for patients whose cancer has resisted standard treatments.
Why it matters
Mantle cell lymphoma can become resistant to current options like BTK inhibitors or CAR T-cell therapy, making new therapeutic targets necessary. By identifying how these cancer cells hide from the body's defenses, scientists may be able to better design future treatments for Houston patients.
A 2026 study analyzed 28 mantle cell lymphoma patient samples via RNA sequencing and 11 specimens via flow cytometry. Researchers found that a CD70-targeting bispecific antibody slowed tumor growth in mice, though the results remain preliminary and require further testing in humans.
The players
MD Anderson Cancer Center
A Houston-based comprehensive cancer center that conducts extensive research into blood cancers and immunotherapies.
The details
Cancer cells often use the CD70-CD27 axis to trigger T-cell exhaustion, effectively switching off the body's immune surveillance. By engineering a CD70 × CD3 bispecific T-cell engager, researchers created a molecule that forces T-cells to attack the tumor. In lab systems, this approach increased the release of tumor-killing markers like interferon-γ and granzyme B while reducing immunosuppressive signals.
Timeline
The preclinical findings were published in 2026.
Health Landscape
This research follows the broader medical shift toward using bispecific T-cell engagers to redirect immune cells against resistant malignancies. The study specifically applies this technology to address the CD70-driven immune evasion that characterizes mantle cell lymphoma progression.
This study is a preclinical report and does not represent a currently available clinical treatment or a change in standard care. If you are managing mantle cell lymphoma, discussions about emerging clinical trials or resistant-disease research are best held with your oncologist.
The takeaway
This research highlights how cancer cells exploit the CD70 pathway to avoid detection, offering a potential pathway for future drug development. Patients should continue to prioritize follow-up appointments with their hematologist-oncologist to monitor for disease progression or new trial options.
Further reading
For more on evolving research, visit our Cancer section.
More information
View the complete Cancer Letters scientific study article for further technical details.
Live Poll
Do you trust that early-stage laboratory medical research will result in successful patient treatments?
